Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Tocagen (TOCA) Competitors

Tocagen logo

TOCA vs. ZYME, MENS, SBTX, MBX, AVTE, NLTX, CYBN, BIOA, VIRI, and WHWK

Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK).

Tocagen vs. Its Competitors

Zymeworks (NYSE:ZYME) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Zymeworks' average media sentiment score of 0.00 equaled Tocagen'saverage media sentiment score.

Company Overall Sentiment
Zymeworks Neutral
Tocagen Neutral

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 21.4% of Tocagen shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zymeworks has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500.

Tocagen has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$93.38M9.95-$118.67M-$1.49-8.95
Tocagen$40K6,936.51-$63.52M-$2.69-4.31

Zymeworks has a net margin of -182.75% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -23.00% beat Tocagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-182.75% -23.00% -18.04%
Tocagen -176,433.34%-327.74%-111.87%

Zymeworks presently has a consensus price target of $21.00, indicating a potential upside of 57.54%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Tocagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Tocagen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Zymeworks beats Tocagen on 11 of the 15 factors compared between the two stocks.

Get Tocagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TOCA vs. The Competition

MetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$277.46M$776.92M$5.70B$9.50B
Dividend YieldN/A4.84%4.58%4.01%
P/E Ratio-4.891.4028.1020.05
Price / Sales6,936.5125.35429.0189.19
Price / CashN/A19.5636.2258.56
Price / Book25.786.798.665.87
Net Income-$63.52M-$4.32M$3.25B$258.55M

Tocagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TOCA
Tocagen
N/A$11.60
+7.9%
N/A+1,753.4%$277.46M$40K-4.8977Gap Down
ZYME
Zymeworks
2.5026 of 5 stars
$14.32
flat
$21.00
+46.6%
+25.4%$997.86M$93.38M-9.55460Upcoming Earnings
MENS
Jyong Biotech
N/A$10.06
-8.5%
N/AN/A$836.30MN/A0.0031Quiet Period Expiration
SBTX
Silverback Therapeutics
N/A$17.85
-0.4%
N/A+60.1%$643.64MN/A-7.3883High Trading Volume
MBX
MBX Biosciences
2.1297 of 5 stars
$11.70
-4.0%
$37.57
+221.1%
N/A$391.06MN/A0.0036News Coverage
AVTE
Aerovate Therapeutics
N/A$8.69
-8.2%
N/A-87.6%$251.88MN/A-2.9120High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$22.34
-1.2%
N/A-46.6%$209.95MN/A-7.1890High Trading Volume
CYBN
Cybin
2.7149 of 5 stars
$7.73
-3.7%
$85.00
+999.6%
N/A$177.98MN/A-1.7650
BIOA
BioAge Labs
N/A$4.76
+3.5%
N/AN/A$164.91MN/A0.00N/AGap Down
VIRI
Virios Therapeutics
N/A$4.83
+1.5%
$5.00
+3.5%
+1,940.6%$93.02MN/A-17.895
WHWK
Whitehawk Therapeutics
N/A$1.87
+1.1%
N/AN/A$87.15M$25.98M11.6940Gap Up

Related Companies and Tools


This page (NASDAQ:TOCA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners